Aligos Therapeutics, Inc. (ALGS) Return on equity 2020–2025
Aligos Therapeutics, Inc. (ALGS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-45.2%FY2025 · since FY2020: -49.3% → -45.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -45.2% | — |
| FY2023 | -95.2% | -2.8 pp |
| FY2022 | -92.4% | -23.0 pp |
| FY2021 | -69.5% | -20.1 pp |
| FY2020 | -49.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice